2 U.S. lawmakers have disclosed 2 Cytokinetics, Inc. trades under the STOCK Act — 2 buys and 0 sells between 2015 and 2026. Congress has been net buyers of CYTK, and their disclosed buys are down 13.8% versus the latest close.
*Notional-weighted price return on lawmakers' disclosed buys of CYTK, marked to the latest close — per-share (share counts aren't disclosed).
1 member disclosed a CYTK purchase in the last 90 days (newest first).
| Date | Member | Type | Amount | Est. price | Latest close | Return |
|---|---|---|---|---|---|---|
| 2026-06-30 | Gilbert Cisneros | BUY | $1K–$15K | $85.19 | $73.45 2026-08-13 | -13.8% |
| 2015-02-24 | Austin Scott | BUY | $1K–$15K | $7.74 | $73.45 2026-08-13 | +849.0% |
Return: buys marked to the latest close (open); sells tagged rt are realized round-trips vs a prior disclosed buy; exit = timing (stock move after the sale, seller's perspective).
2 members of the U.S. House and Senate have disclosed Cytokinetics, Inc. transactions under the STOCK Act — 2 purchases and 0 sales. The full member-by-member breakdown, with dates and dollar ranges, is in the table above.
1 member disclosed a CYTK purchase in the last 90 days — most recently Gilbert Cisneros on 2026-06-30. See the "Lawmakers who bought CYTK recently" section above for the dated list.
Notional-weighted, lawmakers' disclosed CYTK buys are down 13.8% versus the latest close of $73.45. Each trade's own return — and realized round-trips on matched sells — is in the Return column.
Yes. Under the 2012 STOCK Act, members of Congress may buy and sell individual stocks but must publicly disclose each transaction within 45 days. Bargo surfaces those filings so you can see who traded CYTK and how it performed.